Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227.
Julie R BrahmerJong-Seok LeeTudor-Eliade CiuleanuReyes Bernabe CaroMakoto NishioLaszlo UrbanClarisse Audigier-ValetteLorena LupinacciRandeep SanghaAdam PluzanskiJacobus BurgersMauricio MahaveSamreen AhmedAdam J SchoenfeldLuis G Paz-AresMartin ReckHossein BorghaeiKenneth J O'ByrneRavi G GuptaJudith BushongLi LiSteven I BlumLaura J EcclesSuresh R RamalingamPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
With all patients off immunotherapy treatment for ≥ 3 years, nivolumab plus ipilimumab increased 5-year survivorship versus chemotherapy, including long-term, durable clinical benefit regardless of tumor PD-L1 expression. These data support nivolumab plus ipilimumab as an effective first-line treatment for patients with mNSCLC.
Keyphrases